Inviragen Presents Safety and Immune Response Data from a P1 Study of its Two-Dose Dengue Vaccine
Related Posts
EdgeQ Closes $75M Series-B Investment and Ramps to Customers’ Demand for Its Award-Winning 5G+AI Base Station-on-a-Chip for 5G Networks
- 02 05 2023
- |
Proxtera announces successful first close, of Series Seed round of funding with Ant Group, CerraCap Ventures, and EDBI
- 30 03 2023
- |
